Sterol/Stanol Health Claim Comment Period Reopening Likely, FDA Says
This article was originally published in The Tan Sheet
Executive Summary
FDA likely will reopen the comment period on its interim final rule approving a health claim for sterol/stanol esters and coronary heart disease risk reduction, the agency said.